Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)

44.30
Delayed Data
As of May 27
 +1.61 / +3.77%
Today’s Change
9.85
Today|||52-Week Range
46.46
+11.56%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.5B

Company Description

Tetraphase Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops next-generation tetracycline antibiotics that address unmet needs such as the treatment of serious drug-resistant and gram-negative infections. The company's lead product candidate, eravacycline is a fully synthetic tetracycline derivative that is developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections. It has developed an emerging pipeline of potent novel antibiotics that provide a portfolio of intravenous and oral drug candidates with the potential to treat a wide range of infections, including broad-spectrum and selective-spectrum infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.

Contact Information

Tetraphase Pharmaceuticals, Inc.
480 Arsenal Street
Watertown Massachusetts 02472
P:(617) 715-3600
Investor Relations:
(617) 600-7040

Employees

Shareholders

Mutual fund holders43.77%
Other institutional33.22%
Individual stakeholders32.04%

Top Executives

Guy MacDonaldPresident, Chief Executive Officer & Director
John Craig ThompsonChief Operating Officer
David Charles LubnerChief Financial Officer & Senior Vice President
Patrick Taylor HornChief Medical Officer
Maria D. StahlSenior Vice President & General Counsel

To view my watchlist

Not a member yet?

Sign up now for a free account